Date: 2017-02-15
Type of information: R&D agreement
Compound:
Company: Boehringer Ingelheim (Germany) Weill Cornell Medicine (USA - NY)
Therapeutic area: Inflammatory diseases - Respiratory diseases
Type agreement: R&D
Action mechanism:
Disease: chronic obstructive pulmonary disease (COPD)
Details: * On February 15, 2017, Boehringer Ingelheim announced a collaboration with Weill Cornell Medicine to identify new treatment approaches for chronic obstructive pulmonary disease (COPD) in order to develop novel treatments that could possibly halt or even reverse the progression of the disease process. The new, three-year collaboration combines Weill Cornell Medicine’s Department of Genetic Medicine’s understanding of chronic airway diseases and experience in the investigation of novel therapeutic concepts for airway repair with Boehringer Ingelheim’s expertise in the discovery and development of new therapies for respiratory diseases. This collaboration is the second collaboration between Boehringer Ingelheim and Weill Cornell Medicine, following prior work in inflammatory bowel disease (IBD).
Financial terms:
Latest news:
